<DOC>
	<DOCNO>NCT00978237</DOCNO>
	<brief_summary>Eligible HIV-infected patient clinically evident lipoatrophy despite treatment efavirenz fixed-dose combination thymidine nucleoside analogue inform ask enroll study ; randomize ( 1:1 ) two branch , A : EFV + Fixed combination analogue tenofovir + emtricitabine.B ( experimental ) : LPV/r + combination correspondent analogue . The main variable evaluation absolute change limb fat mass 24 month baseline group .</brief_summary>
	<brief_title>Clinical Trial Assess Effect Change Efavirenz ( EFV ) Lopinavir/Ritonavir ( LPV/r ) Lipoatrophy HIV-infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Patients HIV positive &gt; 18 year . Patients treatment Sustiva ( r ) +Truvada ( r ) ; Sustiva ( r ) +Kivexa ( r ) . HIVARN &lt; 50 copies/mL la six month . Clinically evident lipoatrophy ( moderate severe ) . Negative pregnancy test . Signed informed consent . Evidence failure mutation therapy protease inhibitor . Patients treat LPV/r . Mild lipoatrophy . History alcoholism drug addiction discourage participation study . Pregnancy breastfeed . Documented current 4 week prior opportunistic infection . Creatinin clearance &lt; 60mL/min . Concomitant use nephrotoxic drug immunosuppressant . Actual treatment systemic corticosteroid , IL2 chemotherapy . Patients treatment drug investigation . Acute hepatitis . Any disease discourage participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>HIV - Lipoatrophy</keyword>
	<keyword>treatment experience</keyword>
</DOC>